Early deadline alert: register for #ESMO24 by 12 June! The congress takes place from 13 to 17 September in Barcelona and online. Get cutting-edge insights in oncology, high quality educational sessions, and a wide range of networking opportunities with global experts & peers.

🔍 This comprehensive review delves into the transformative power of #AI in cancer research, from boosting productivity to uncovering new scientific discoveries. A must-read for oncologists and researchers...on your day to Chicago! #Oncology nature.com/articles/s4156…

#INAVO120 👩🏼 w/ 1) PI3 mutation AND 2)relapse within 12 months of adj ET Fulvestrant + palbo +/- inavolisib: PFS improved 7.3 to 15.0 mo Time to chemo prolonged HR 0.54 AEs include: BG 🍬, diarrhea 💩, rash, and stomatitis 😫...but discontinuations very rare #ASCO24 #bcsm

Fabulous presentation by Antonio Giordano, MD PhD on data with enfortumab vedotin for HER2- MBC TNBC ORR 19% ER ORR 15.6% Response not dependent on Nectin4 expression Dana-Farber’s Breast Oncology Center OncoAlert #ASCO24

A lot of discussion these days around ER-low. We present data in >1200 MBC including prognosis, switch from primary tumor, TILs and data from the TONIC trial! Stop at poster board 78! #ASCO24 Federica Miglietta MarleenKokLab

Kudos to my forever friend Antonio Giordano, MD PhD #ASCO24

DB-06 Practice-changing data elegantly presented by G Curigliano MD PhD

Fantastic talk by Giampaolo Bianchini at #ASCO2024 : "Does the Target Matter?" re ADCs. Must say, the insights were top-notch! But full disclosure: I might be a bit biased! 😅 #CancerResearch #ADCs

Excited to share that the DESTINY-06 trial was presented at #ASCO2024 and received fantastic feedback from our outstanding audience! A huge thank you to everyone who attended and supported our work in advancing cancer treatment. Together, we’re making strides in oncology!

Thrilled to announce the publication of the final overall survival data of DESTINY-03 in Nature Medicine, coinciding with its presentation at #ASCO2024! This marks a significant milestone in our fight against cancer. Thank you to everyone involved for your dedication and support!

#PALMERES-2 🇮🇹 real world efficacy study of 1st L CDK4/6 Ribo & abema showed ⬆️ rwPFS in premeno and luminal B disease and overall all pts All 3 showed 🟰 rwPFS in older & bone only pts Hmmm...again suggests palbo isn't really the same #ASCO24 #bcsm

🌟 Don't miss your chance to shape the future of ESMO! Vote for G Curigliano MD PhD for President and support a vision dedicated to innovation and global collaboration in cancer care. Make your voice heard and vote today! 🗳️ESMO - Eur. Oncology

Unmissable opportunity for young oncologists!

🔥Exercise is crucial for patients, and doctors need to know❗️ While reducing risk of recurrence is a key benefit (see 👇👇👇👏👏👏), it's not the only one. Encourage your patients to exercise—they'll experience numerous health benefits and will thank you! Journal of Clinical Oncology #BCSM

Just a few hours left to vote for the next ESMO President! My choice is ⁦⁦G Curigliano MD PhD⁩. Make your voice heard and vote now! ⁦ESMO - Eur. Oncology⁩ esmo.org/about-esmo/how…

Have a look to this paper on Eur J Cancer by the Italian #PRO4All project, to help researchers choosing #PROMs for pts with cancer The development of an Archive of Patient-Reported Outcome Measures (PROMs) in Oncology: The Italian PRO4All Project ejcancer.com/article/S0959-…

Huge congratulations! G Curigliano MD PhD

Based on CAPItello-291: Capivasertib plus fulvestrant approved in the EU for patients with advanced ER-positive breast cancer with PIK3CA, AKT1 or PTEN alterations astrazeneca.com/media-centre/p…

⁦ESMO - Eur. Oncology⁩ recommendations to homogenize NGS reports has been published. Any thoughts? 💭 sciencedirect.com/science/articl…

Thrilled to share this work, which sheds light on a reality we often overlook. Proud to be a co-author of this eye-opening study! #bcsm #Immunotherapy Congrats Marco Mariani